Hematology-Oncology
Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models
MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.
